

United States Patent and Trademark Office

4

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO. FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
10/786,076 02/26/2004		Henrik Stender	9138.0006-03	3526		
22852	7590 05/22/2006		EXAMINER			
FINNEGAN	, HENDERSON, FAI	FREDMAN, JEFFREY NORMAN				
LLP		ART UNIT	PAPER NUMBER			
	RK AVENUE, NW		FAFER NOMBER			
WASHINGIC	ON, DC 20001-4413	1637				
		DATE MAILED: 05/22/2006				

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No. Applican		Applicant(s)	ant(s)				
		10/786,076	3	STENDER ET AL.					
Office Action Summary			Examiner		Art Unit				
			Jeffrey Free	dman	1637				
Period fo	The MAILING DATE of this commun r Reply	nication appo	ears on the	cover sheet with the c	orrespondence ad	dress			
WHIC - Exter after - If NC - Failu Any	ORTENED STATUTORY PERIOD F CHEVER IS LONGER, FROM THE N SIX (6) MONTHS from the mailing date of this come of period for reply is specified above, the maximum some to reply within the set or extended period for reply reply received by the Office later than three months and patent term adjustment. See 37 CFR 1.704(b).	MAILING DA s of 37 CFR 1.13 munication. tatutory period wi y will, by statute,	ATE OF THI 66(a). In no ever fill apply and will cause the applic	S COMMUNICATION it, however, may a reply be time expire SIX (6) MONTHS from tation to become ABANDONEI	I. lely filed the mailing date of this co O (35 U.S.C. § 133).				
Status									
1)	Responsive to communication(s) file	ed on							
2a)□	This action is FINAL . 2b)⊠ This action is non-final.								
3)□									
,—	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.								
Dispositi	on of Claims								
4)⊠	4)⊠ Claim(s) <u>1-36</u> is/are pending in the application.								
	4a) Of the above claim(s) is/are withdrawn from consideration.								
5)	5) Claim(s) is/are allowed.								
6)□	6) Claim(s) is/are rejected.								
7)									
8)⊠	Claim(s) <u>1-36</u> are subject to restrict	ion and/or e	election requ	iirement.					
Applicati	on Papers								
9)[The specification is objected to by th	ne Examiner	r.						
10)	The drawing(s) filed on is/are	: a) <u></u> acce	epted or b)[\cline{oxed} objected to by the \cline{oxed}	Examiner.				
	Applicant may not request that any object	ection to the o	drawing(s) be	held in abeyance. See	e 37 CFR 1.85(a).				
	Replacement drawing sheet(s) including	g the correction	on is require	d if the drawing(s) is obj	ected to. See 37 Cl	FR 1.121(d).			
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.									
Priority ι	ınder 35 U.S.C. § 119								
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:									
	1. Certified copies of the priority documents have been received.								
	2. Certified copies of the priority documents have been received in Application No								
	3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).								
* See the attached detailed Office action for a list of the certified copies not received.									
Attachmen	t(s)								
	e of References Cited (PTO-892)		Interview Summary (PTO-413) Paper No(s)/Mail Date						
Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)				Paper No(s)/Mail Da		D-152)			
	r No(s)/Mail Date			6) Other:					

Application/Control Number: 10/786,076 Page 2

Art Unit: 1637

DETAILED ACTION

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - Claims 1-24, 35, and 36, drawn to PNA probes, classified in class 536, subclass 23.1.
 - Claims 25-34, drawn to methods of detection of mycobacteria, classified in class 435, subclass 6.

The inventions are distinct, each from the other because of the following reasons:

- 2. Inventions Group I and in Group II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product. See MPEP § 806.05(h). In the instant case, the products of Group I can be used for the detection method of Group II, for nucleic acid purification methods, or as tags in DNA hybridization methods..
- 3. Because these inventions are independent or distinct for the reasons given above and the inventions require a different field of search (see MPEP § 808.02). In particular, the search for the products will not necessarily identify art on the method claims. For example, a PNA probe which is identical to a mycobacterial sequence, but was designed and used for a different organism, would anticipate the product claims such as claim 1, but would not address the requirement in claim 28 of relating the target

Application/Control Number: 10/786,076 Page 3

Art Unit: 1637

sequence amount to the presence of mycobacteria. Therefore, separate searches are required for the probe and for methods which will involve the use of separate search terms, separate lines of analysis and which may result in the citation of different art.

Therefore, restriction for examination purposes as indicated is proper.

4. Further Restriction Requirement Applicable to both Groups:

Additionally, each group named above is subject to a further restriction. Applicant is required to further elect two (2) sequences (one MOTT and one MTC) as appropriate for the Group selected. This is NOT an election of species. Nucleotide sequences encoding different proteins are structurally distinct chemical compounds and are unrelated to one another. These sequences are thus deemed to normally constitute independent and distinct inventions within the meaning of 35 U.S.C 121. Absent evidence to the contrary, each such nucleotide sequences are presumed to represent an independent and distinct invention, subject to restriction requirement pursuant to 35 U.S.C. 121 and 37 CFR 1.141. By statute, "[i]f two or more independent and distinct inventions are claimed in one application, the Commissioner may require the application to be restricted to one of the inventions." 35 U.S.C. 121. Pursuant to this statute, the rules provide that "[i]f two or more independent and distinct inventions are claimed in a single application, the examiner in his action shall require the applicant...to elect that invention to which his claims shall be restricted." 37 CFR 1.142 (a). See also 37 CFR 1.141(a).

The search and examination of all possible groups would pose an enormous burden on the examiner and on the PTO search resources. Because these inventions

are distinct for the reasons given above and have acquired a separate status in the art as demonstrated by their different classification and recognized divergent subject matter due to all of the inventions' different gene sequences would require different searches that are not coextensive, examination of these claims would pose a serious burden on the examiner and therefore the restriction is deemed proper.

5. The examiner has required restriction between product and process claims.

Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See

Art Unit: 1637

"Guidance on Treatment of Product and Process Claims in light of *In re Ochiai, In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder.

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

6. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions

Application/Control Number: 10/786,076 Page 6

Art Unit: 1637

unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey Fredman whose telephone number is (571)272-0742. The examiner can normally be reached on 6:30-3:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on (571)272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

> Jeffrey Fredman **Primary Examiner**

Art Unit 1637